Clinical trial
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain…
NCT00126386 · Alberta Health services, Other · Completed
Key facts
| NCT number | NCT00126386 |
|---|---|
| Title | Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community |
| Official title | Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study |
| Lead sponsor | Alberta Health services, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cancer, Hypercalcemia, Pain |
| Intervention type | Drug |
| Interventions | Zoledronic acid (Zometa) |
| Enrollment | 11 |
| Start date | Jan 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Aug 4, 2005 |
| Last update posted | Nov 21, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: